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Abstract
Reverse phase protein microarray technology was used to study key signaling pathways thought to
be involved in the progression of benign epithelium to the lethal phenotype of prostate cancer.
Specimens of androgen-stimulated localized prostate cancer (N=21) and androgen-deprivation
therapy-recurrent local (N=4) or metastatic (N=11) prostate cancer were laser capture microdissected
prior to analysis. The results showed significant increases in protein expression levels in malignant
epithelial cells and patient-matched stromal tissue, which included higher levels of the apoptotic
proteins Bax and Smac/Diablo and increased phosphorylation of Bcl2 (S70). The mitochondrial
protein Smac/Diablo and the transcription regulatory protein STAT3 (Y705) correlated with Gleason
sum and differed statistically in high Gleason grade (8-10) prostate cancers. Distinct metastasis-
specific pathways were activated by caspase cleavage activation, ErbB2 phosphorylation, Bax total
protein and Bcl-2 phosphorylation while phosphorylation of all three members of the MAPK family,
ERK, p38 and SAP/JNK, were reduced significantly in metastatic lesions compared to primary
cancers. This study, the most comprehensive pathway analysis ever performed for human prostate
cancer, presents evidence of specific pathway biomarkers that may be useful for assessment of
prognosis and stratification for therapy if validated in larger clinical study sets.
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Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in United States
males and the second leading cause of cancer death1. Despite declining mortality and migration
towards lower stage disease, 3.5% of men still present with locally advanced or metastatic
disease 2. Additionally, up to 35% of men presenting with clinically localized disease will fail
local therapy 3, 4. First line treatment for men who progress after failing local therapy or for
those men who present with advanced or metastatic disease is most commonly androgen
deprivation therapy (ADT), which is not considered curative since most cancers recur as a
lethal phenotype for which most treatments are ineffective. Despite recent advances in
cytotoxic chemotherapy for ADT-recurrent prostate cancer5, 6, overall survival fro these
patients remains less than 2 years. Clearly, a better understanding of the molecular pathogenesis
of prostate cancer is needed along with more effective treatments for clinically aggressive and
metastatic disease.
Recently, a number of publications have shown that a number of types of human solid cancers
are driven by pathway derangements7-9. Indeed, these recent findings highlight that while
mutations underpin cancer, and each patient has a seemingly distinct mutational fingerprint,
at a functional level, the mutational hits coalesce into distinct pathway effects and reveal that
cancer is a protein pathway disease. Advancements in molecular technologies have led to the
need to determine protein function in the complex cellular environment, and how protein
pathways are linked and coordinately regulate cellular function10. The use of protein-directed
technologies is needed because gene expression analysis cannot accurately predict protein
expression nor catalog the post-translationally driven activation (such as by phosphorylation)
that orchestrates signaling11-13. Cell culture systems and animal models may not accurately
reflect these changes13. Finally, most current therapies are directed at protein targets and these
targets are often protein kinases, their substrates, or both. The activation states of these proteins
and networks fluctuate constantly depending on the cellular microenvironment. Consequently,
the application of molecular profiling to provide individually tailored therapy should include
direct proteomic pathway analysis of patient material. Moreover, because the cellular kinome
represents a rich source of new targets for molecular therapeutics, technologies that can profile
and assess the activity of these molecules in human tissues are critical for realization of patient-
tailored therapy14.
A new protein micorarray technology, reverse phase protein arrays (RPMA), allows for study
of protein signaling pathways15-18 and measurement of up to hundreds of signaling proteins
and their degree of phosphorylation in tissue biopsy samples.19 Coupling laser capture
microdissection (LCM) to RPMA profiling was shown recently to be a necessary for accurate
analysis of malignant epithelium signaling portraits 19. Previous publications have shown the
feasibility of RPMA-driven cell signaling analysis of patient-matched stroma, malignant
epithelium and normal/benign epithelium from prostate cancer patients16. The current study
expands upon this earlier feasibility work and more thoroughly investigates stromal-epithelial
cell signaling changes in the context of human prostate cancer, and investigates whether




A total of 25 prostate cancer specimens were used for this study, which resulted in 24 patient
matched cases of laser capture microdissected malignant tumor, stroma and benign epithelium
being procured, with one case where only malignant tumor epithelium was procured. All tissue
was procured under full patient consent and IRB approval. Six frozen radical prostatectomy
Grubb et al. Page 2













(RP) specimens were received from Catholic University, Santiago, Chile and 4 transurethral
resection specimens of ADT-recurrent locally advanced or metastatic prostate cancer that
caused urinary retention were received from University of North Carolina, Chapel Hill, NC.
Fourteen RP samples were ethanol-fixed, paraffin-embedded tissues collected at the National
Cancer Institute or the National Naval Medical Center. Pathologic Gleason scores ranged from
2+3 = 5 to 5+4 = 9. Seventeen patients had Gleason sum= 4-7 and 5 patients had Gleason sum
score = 8-10. Eleven metastatic cancer specimens were procured under a rapid autopsy protocol
at the University of Michigan20. Autopsies were performed within 4 hours of death, with the
average length of time between death and tissue procurement 1 hour 30 minutes. Of these 11
samples of metastases, 5 were from soft tissue, 4 from liver, 1 from bone and 1 from lung. The
specimens were sectioned using uncharged slides for microdissection.
Tissue processing and microdissection
Frozen tissues were embedded in OCT prior to sectioning, and all specimens were sectioned
at 8 μm onto uncharged slides for LCM. Representative sections from each case were stained
with hematoxylin/eosin and reviewed by a pathologist to confirm presence of cancer. Slides
were deparaffinized or ethanol-fixed and stained with hematoxylin as described previously21,
22. LCM of benign, stromal and malignant cells was carried out using a PixCell 2 Laser Capture
Microdissection System (Arcturus Engineering; Mountain View, CA, USA). Three to five
thousand LCM shots (7.5–30 μm size, 1–7 cells/shot) were acquired for each tissue type.
Cell lysis and reverse-phase array printing
Microdissected cells were lysed for 30 min at 75–77°C using a 1:1 mixture of 2× SDS sample
buffer and tissue protein extraction reagent ( TPER, Pierce, Rockford, IL, USA) in volumes
corresponding to 3-4000 shots/20 μL (stroma and benign glands) or 5000 shots/20 μL (tumor).
Cell lysates were stored at -80°C prior to printing. A total of 85 microdissected tissue lysates
were separated into 2 groups and approximately 40nL of lysate was printed in duplicate onto
nitrocellulose-coated glass slides (FAST Slides, Schleicher and Schuell, Keene, NH) with an
Aushon 2470 solid pin microarrayer (Aushon Biosystems, Billerica, MA, USA) equipped with
325 μm pins. Samples were printed in 5 point, 1:2 serial dilution curves and 50 slides were
printed for each group. Three stromal samples with sufficiently large lysate volume were
included in both groups and served as bridging cases between arrays; A431 and A431 + EGF
cell lysates (BD Biosciences, San Jose, CA, USA) were printed on both arrays and used to
normalize data between arrays. Slides were stored dessicated at -20°C prior to staining with
antibody.
Protein microarray staining
For estimation of total protein amounts, selected arrays were stained with Sypro Ruby Protein
Blot Stain (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions and
visualized on a Kodak ImageStation (Eastman Kodak, Rochester, NY, USA). Printed slides
were prepared for staining by treating with 1× Reblot (Chemicon, Temecula, CA, USA) for
15 min, followed by 2×5 min washes with PBS. Slides were treated overnight with blocking
solution (1g I-block(Applied Biosystems, Bedford, MA, USA), 0.5% Tween-20 in 500mL
PBS) with constant rocking at 4°C. Staining used an automated slide stainer (DAKO,
Carpinteria, CA, USA) using a biontinyl-linked peroxidase catalyzed signal amplification
system as per the manufacturer’s recommendation and components from the manufacturer’s
kit, unless otherwise indicated as previously described 21. Slides were stained with a set of 39
antibodies antibodies against phosphorylated or total forms of proteins involved in cell
proliferation, survival, motility and apoptosis signaling. A complete list of antibodies, sources
and dilutions used for these experiments is available in Supplementary Table 1. All antibodies
were subjected to extensive validation for single band, appropriate MW specificity by Western
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blot as well as phosphorylation specificity through the use of cell lysate controls (e.g. Hela +/-
pervandate, Jurkat +/- Calyculin).
Image analysis
Stained slides were scanned individually on a UMAX PowerLook III scanner (UMAX, Dallas,
TX, USA) at 600 dpi and saved as TIF files in Photoshop 7.0 (Adobe, San Jose, CA, USA).
The TIF images for antibody-stained slides and Sypro-stained slide images were analyzed using
MicroVigene v2.8.1.0 (VigeneTech, Carlisle, MA, USA). Briefly, final data values for each
sample were calculated using the factor average mode, and all values were negative control
subtracted and normalized to total protein staining via SYPRO dye within the analysis. These
data values were normalized to either the A431 or A431 + EGF data value to facilitate
comparison of sample values between paired arrays stained with the same antibody.
Statistical Analysis
Two-way, unsupervised hierarchical clustering and one-way analyses were carried out using
JMP v5.1.2. (SAS Institute, Cary, NC, USA). Statistical comparisons and correlations among
various groups of samples were conducted using the R statistical software v2.7.2 (R
Development Core Team (2008). R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL
http://www.R-project.org.)
Results and Discussion
LCM was used to procure pure populations of patient-matched tumor and benign epithelium
along with stromal cells from 24 patients in order to more fully elucidate stromal-epithelial
cell signaling differences in prostate (the 25th sample yielded only malignant tumor epithelium
via LCM). Unsupervised hierarchical clustering analysis (Figure 1) of 38 protein signaling
endpoints chosen for measurement based on their key roles in tumorigenesis revealed a high
degree of patient-specific signaling. While there was definite clustering of stromal (in blue)
and benign (in green) cell populations, malignant epithelial signatures appeared more diverse.
However, malignant, benign and stromal signatures often clustered together, which indicates
more similarity of pathway activation within a patient regardless of cell type than among the
same cell type across many patients. Patient-specificity in signal profiling has been shown
previously in ovarian23 and breast19 cancers and reinforces the concept of patient-specific
therapy. Recently, analysis of stromal-epithelial signaling in colorectal cancer tissue using the
same approach revealed distinct signaling changes between the stromal and malignant
epithelial compartments24.
Standard statistical mean comparison identified several pathway changes that were cell type-
specific. An unsupervised clustering heatmap display of the 3 statistically significant endpoints
(figure 2) showed that annexin I and II and phosphorylation of p38 (T180/Y182) are more
highly expressed/activated in the normal/benign epithelial cell population than patient-matched
malignant epithelial cells. Loss of expression of annexin I and II during tumorigenesis has been
shown to play a direct functional role in normal cellular function of benign prostate
epithelium25-27. The observed decrease in phopshorylated p38 in malignant epithelium
compared to matched normal/benign cells warrants further exploration. Other MAPK proteins
(e.g SAP/JNK, ERK) were not affected similarly so the significance of this observation in the
context of tumorigenesis and the tumor microenvironement remains uncertain.
Stromal-malignant epithelial comparisons yielded a larger number of endpoints that differed
statistically (Figure 3). A number of these proteins, such as Bax, Smac/Diablo, and cleaved
caspase 9, are critically important for regulating apoptosis. In prostate cancer, Bcl-2 has been
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found to be important in progression and resistance to treatment with ADT, chemotherapy, and
radiation28. A high Bcl-2 to Bax ratio has been associated with resistance to radiation
treatment29. Antisense oligonucleotide to Bcl-2 and Bcl-xL increased the sensitivity of LNCaP
cells to treatment with docetaxel and paclitaxel28. A number of proteins involved in EGFR
signaling, including EGF and c-erbB2 receptors, downstream MEK-ERK signaling
components and STAT3 signaling molecules, were more highly phosphorylated in malignant
epithelium compared to stroma. EGFR family signaling is one of the most intensely studied
pathways in oncology and its importance in therapeutic targeting of prostate cancer is well-
known30, 31.
Several researchers have investigated the interaction or “cross-talk” between prostate stroma
and epithelium32. This interaction is thought to be especially important in the development of
metastases, particularly bone metastases. In addition to in vivo animal experiments, recent
research using human prostate biopsy specimens has shown that stromal pathology can be
correlated with patient outcomes. Yanagisawa et al examined 224 human prostate biopsy
specimens from patients who subsequently underwent radical prostatectomy33. They found
that reactive stromal grading was an independent predictor of biochemical recurrence.
Thus, it appears that there are a number of significant pathway differences between different
selected cell types in the human clinical study set analyzed, with malignant epithelium more
similar to benign epithelium than stroma adjacent to cancer. The utility of LCM to provide this
type of careful molecular profiling is revealed by such an analysis, and provides justification
for a more careful field effect. Stroma nearby and far away from malignant epithelium should
be analyzed so that questions concerning the potential effects of epithelium-mesenchymal
transition on signaling pathways can be studied directly; such studies have been undertaken in
colorectal cancer24. Further understanding of the signaling activation of stroma surrounding
prostate cancers may increase the number of potential therapeutic targets.
No phosphoprotein endpoints were associated with pathological T-stage. Many of the localized
cases were from radical prostatectomy specimens and these cases were clinically localized
(cT1-T2). Many of these were demonstrated to have extraprostatic extension on final
pathology; in general, in cases where the final pathologic stage was available, the T stage was
between pT2b and pT3a, thus reducing the likelihood that stage-dependent variation in
signaling might be found.
Pathway markers that could have direct translational/clinical value were sought by evaluating
whether pathway signatures from primary malignant epithelium were similar to signaling
within epithelium from distant metastasis and if pathway markers existed that correlated with
Gleason score. Signaling activation portraits of LCM-procured malignant epithelium from
frozen metastasis tissue samples from bone, liver, lung and soft tissue sites from 11 patients
were compared to the malignant epithelium from the prostate primaries of 25 other patients.
Unsupervised clustering analysis identified endpoints that distinguished metastatic epithelium
from primary malignant epithelium (Figure 4). Clear separation of the metastatic epithelium
was seen, regardless of site of metastasis, which was driven largely by c-erbB2 levels and
phosphorylation of c-erbB2 (Y1248), Bcl-2 phosphorylation (S70), Bax, STAT 3
phosphorylation (Y705) and elevated caspase cleavage (Figure 4,5). The phosphorylation of
3 major members of the MAPK family, ERK, p38 and SAPK/JNK, was lower in malignant
epithelium in metastases compared to primary sites (Figure 4,5). These metastasis-specific
changes do not appear to be prognostic within this study set since no correlation with Gleason
sum score was seen (Figure 5).
STAT3 phosphorylation has been associated with both tumor initiation and progression34.
STAT3 activation has also been shown to be specifically associated with malignant
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transformation of prostatic epithelial cells35. The transforming ability of STAT3 in cancers
seems to require its constitutive activation by aberrant growth factor signaling36. STAT3 also
correlated with high Gleason sum (8-10), although this correlation was not found in this study
set.
The exact role of ErbB2 (Her2) in prostate cancer is not well understood, but is a known drug
target for CaP that is under intensive investigation. Determination of Her2 status has been
shown to be critically important in breast cancer treatment decisions and management, and the
success in targeting the Her2 receptor in breast cancer has prompted studies of Her2 in prostate
cancer. While this study is the most detailed signaling analysis of prostate cancer metastasis
to date, it has been shown that total HER2 can be overexpressed in prostate cancers, which has
been shown recently to correlate with metastatic potential37, 38. However, strategies targeting
Her2 did not demonstrate the same clinical efficacy in prostate cancer as observed in breast
cancer39, 40. Recently, her2-directed vaccine trials for prostate cancer have shown some
promise41 However, previous studies have failed to measure phosphorylated HER2 in either
local or metastatic prostate cancer, and the phosphorylated level of HER2 correlated most
strongly with response to herceptin therapy42. These results, if validated in larger study sets,
suggest the potential for selecting men with metastatic prostate cancer for anti-c-erbB2 therapy
based upon phosphorylated/activated her2 status.
Cell signaling analysis comparisons between specimens of primary and metastastic prostate
cancer could be confounded by processing delays of the metastatic material and lack of patient-
matching. Protein degradation appears an unlikely explanation for differences since protein
profiles were not always decreased in metastatic compared to primary sites (figure 6). The
elevation of Bax protein and caspase cleavage in malignant epithelium from metastases
compared to primary tumors probably reflect real biology but could reflect apoptotic events at
time of death prior to necropsy and tissue procurement. Obtaining abundant fresh prostate
metastatic material is difficult because of the limited role for surgical resection in metastatic
prostate cancer. Although the primary tumor is accessable for study, metastases are the lethal
phenotype of this disease. If study of larger study sets reveals potential metastasis-specific
signaling events, direct biopsy of metastatic sites may be justified to guide accurate therapy.
An important aspect of the study was also the careful attention to sample handling and
processing for the tissue samples at each institution since all of these specimens were part of
ongoing molecular profiling efforts. Each tissue, except for those collected under warm
autopsy, were immediately snap frozen on dry ice within 15 minutes after procurement, or
subjected to ETOH fixation. Previous publications from our laboratory whereby patient-
matched frozen and ETOH-fixed paraffin embedded tissue were directly compared by
proteomic analysis, have indicated that there is no discernable differences in the protein profiles
between frozen and ETOH fixation 43. While cell signaling changes within metastatic tissue
could be influenced by tissue procurement differences compared to the primary tissue, our
finding of increased c-erbB2 phosphorylation in metastatic lesions is supported by recent
literature as previously described above. Nevertheless, our metastasis-specific pathway
biomarker findings of course need to be further validated in independent study sets
Differences in signaling between the primary tumor and metastatic lesions have important
therapeutic implications. As molecular markers are identified to guide therapy, reliance on
analysis of pathologic material will become critical. It will be important to determine whether
the signaling characteristics of metastatic lesions and the primary tumor are similar. The results
suggest that there may be differences in signaling between the primary site and metastatic
lesions. Previous studies in breast cancer have shown similarities in gene expression profiles
between the primary tumor and metastatic sites 44. However, other researchers have shown
important differences between primary tumors and their metastases 45. To our knowledge,
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analysis of cell signaling changes between primary tumor and metastatic tumor has not been
explored in prostate cancer. The treatments for each of the men, who were all castrate, whereby
metastatic tissue was obtained was highly heterogeneous, with each patient receiving different
duration of treatment, types of androgen deprivation therapy and chemotherapy regimens. Most
patients underwent either primary or palliative radiation. Despite this heterogeneity and the
location of the metastatic tissue itself, the signaling portraits of the metastatic tissue were
broadly similar. However, the direct impact of the treatment itself on signaling portraits
obtained is unknown since the tissue was procured at least a few months after the last therapy
and in some cases a few years after the last therapy. Since no molecular targeted kinase-directed
inhibitors were used on these patients, it is unclear which, if any, signaling endpoint(s) were
changed in response to treatment. However, it is certainly likely that the signaling portraits
were changed in the residual cells that grew back and/or survived the therapy(ies). Indeed,
these metastatic lesions may be comprised of prostate cancer stem cells that have been shown
to be inherently resistant to most therapies in cell culture and animal models 46. Further work
is required to understand the significance of hormonal, chemotherapy and radiation-mediated
treatment effects on tumor cells in vivo as well as the potential role of prostate cancer stem
cells in the metastatic process. Nonetheless, rational therapy of metastatic prostate cancer
disease using molecular targeted pathway inhibitors will require an understanding of the
ongoing pathway activation of those cells within the metastatic lesion, regardless of prior
treatment regimens.
Finally, we sought to uncover the existence of potential prognostic pathway markers of prostate
cancer aggressiveness., Smac/Diablo and phosphorylated STAT3 (Y705) were found elevated
using univariate analysis in malignant epithelium from patients with histologically more
aggressive cancer (Gleason sum = 8-10) compared to patients with histologically less
aggressive cancer (Gleason sum = 5-7). The potential role of STAT3 activation in prostate
cancer tumorigenesis was described earlier. Smac/Diablo was elevated in high Gleason score
cancers that is unexpected given its known apoptosis-inducing role in cellular function. This
finding will require validation, but a potential hypothesis is that compensatory signaling
pathways are activated by negative feedback loop(s) as cellular control mechanisms attempt
to slow down aberrant cell growth 47. Elevation of Smac/Diablo was not noted in metastatic
prostate cells compared to primary tumors, nor was it elevated in the malignant epithelium
from the 4 patients with clinically advanced tumors. While increased cleaved caspase 3 and 9
levels were elevated in malignant epithelium from metastatic versus primary sites, since
patients with clnically advanced tumors and patients with metastatic disease have tumors are
androgen resistant, it is intriguing that the pro-apoptotic protein Smac/Diablo is lower in those
cells from tumors that are androgen independent and have a more advnced phenotype. This
result will also require further validation in larger cohorts of samples.
Concluding remarks
LCM can be used to procure enriched cell populations 19 that provide the opportunity to begin
to elucidate cell type-specific signaling changes within the complex prostate tissue matrix and
the very different microenvironments encountered at sites of metastases. With the proliferation
of molecularly targeted therapeutics, the identification, characterization and monitoring of
signaling events within actual human primary and metastatic tissues will be essential for
patient-tailored therapy. This study represents the most comprehensive direct pathway and
drug target activation analysis ever performed using prostate cancer clinical specimens with
both androgen dependent and androgen independent signaling as well as prosate tumor cells
within the metastatic microenvironment. Stromal and epithelial-specific signaling changes
were observed and provide the basis for further mechanistic studies. The results indicate that
pathway changes in LCM-procured metastatic cells transcend site of metastasis and may
provide for new therapeutic strategies for metastatic disease or prevention of the development
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of metastatic disease. These signaling pathway alterations were not predictable based on
analysis of the malignant epithelium in the primary and indicate that effective treatment of
metastatic prostate cancer using targeted kinase-directed therapies requires interrogation of the
metastatic cancer itself.
Given the current limited role for tissue biopsy and surgical resection for treatment of metastatic
prostate cancer, opportunities to study metastatic human prostate cancer tissues are few. As a
result, little is known about metastasis-specific molecular alterations. These and other data
warrant establishment of a biorepository of metastatic prostate cancer specimens. Future
studies should investigate if signaling changes within the metastatic lesion are causal to the
metastatic process and targetable.
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Two-way, unsupervised hierarchical cluster map of microdissected, patient-matched malignant
or benign epithelial and stromal cell populations. Samples are designated by case number
followed by C=cancer (black), B=benign (green) or S=stroma (blue).
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Two-way, unsupervised hierarchical cluster map of statistically different endpoints between
malignant and benign tissue groups. Samples are designated by case number followed by
C=cancer (black) and B=benign (green).
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Two-way unsupervised hierarchical cluster map of statistically different endpoints between
malignant and stroma tissue groups. Samples are designated by case number followed by
C=cancer (black) and S=stroma (blue).
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Two-way unsupervised hierarchical cluster map of statistically different endpoints between
malignant and metastatic tissues. Samples are designated by case number followed by
C=cancer (black) and MET=metastasis (red).
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One-way analyses of statistically different endpoints between Gleason sum 5-7 and Gleason
sum 8-10 tumors. Means for each group are indicated by a long green line, and standard
deviations are indicated by short blue lines.
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One way analyses of selected statistically different endpoints between primary and metastatic
sites. Cancers are separated into Gleason sum 5-7 and 8-10. A. Comparison of MAP kinase
family activation levels between primary and metastatic site groups. B. Comparison of Bax,
Bcl-2 S70, total ErbB2 and ErbB2 Y1248 levels between primary and metastatic site groups.
Means for each group are indicated by a long green line, and standard deviations are indicated
by short blue lines.
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